Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 40 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 158 X users
patent: 11 patents
facebook: 3 Facebook pages

wikipedia: 4 Wikipedia pages
reddit: 2 Redditors
video: 1 YouTube creator
guideline: 5 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 530 Mendeley

So far, Altmetric has seen 189 X posts from 158 X users, with an upper bound of 1,698,250 followers.

https://t.co/c1i4h61koz

RT @Innov_Medicine: Treatment and Management: Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma @NEJM https://t.co/r…

Treatment and Management: Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma @NEJM https://t.co/rXlfJVNhTG https://t.co/RmYILXRsa8

RT @Innov_Medicine: Treatment and Management: Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma @NEJM https://t.co/ff…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 185 additional X posts.